射频导管消融进行心房-肺和/或上腔静脉电隔离治疗阵发性心房颤动

目的　总结射频导管消融行心房 肺和 /或上腔静脉 (大静脉 )电隔离治疗阵发性心房颤动 (房颤 )的疗效。方法　选择发作频繁、症状明显 ,药物治疗无效的 10 0例阵发性房颤患者 ,男性 72例、女性 2 8例 ,年龄 2 7～ 75(54± 10 )岁 ,均无瓣膜病等器质性心脏病依据。在环状标测电极导管 (Lasso导管 )指导下行心内电生理标测和心房 靶大静脉 (指术中标测证实为房颤相关的肺静脉或上腔静脉 )电隔离和 /或经验性大静脉电隔离 (指术中无心律失常发作而不能明确房颤相关大静脉 ,主要对双上肺静脉和左下肺静脉进行电隔离 )。结果　 10 0例患者共接受电隔离治疗 12 0次。行单纯心房 靶大静脉电隔离 2 2例 ,经验性大静脉电隔离 78例 ,共电隔离大静脉 2 68根 ,其中肺静脉 2 44根 ,上腔静脉 2 4根。即刻电隔离成功 2 57根 (96% )。平均随访 (2 2 9± 177)d ,随访期内停用所有抗心律失常药物 (部分患者服小剂量β受体阻滞剂 ) ,无房颤发作 65例 (65% ) ,房颤发作明显减少 12例 (2例服用胺碘酮后 ,12 % ) ,总有效率 77%。并发症包括脑卒中 2例 ;肺静脉狭窄 9例 ,其中单支轻度狭窄 7例 ,2支重度狭窄 1例(均为 2次消融 ) ,左上肺静脉完全闭塞 1例 ;术后心包积液 2例。并发症的总发生率为 13 %。结论　(1)使用Lasso导管     

阵发性心房颤动大静脉电隔离后肌袖内自发电活动的特点

目的　总结阵发性心房颤动 (房颤 )患者大静脉 (肺静脉和 /或上腔静脉 )电隔离治疗后肌袖内自发电活动的特点 ,探讨其临床意义。方法　顽固性特发性房颤患者 ,在环状标测电极导管指导下行心内电生理标测以及肺静脉和 /或上腔静脉肌袖的射频导管消融电隔离治疗 ,电隔离后继续留置环状标测导管 10～ 2 0min ,观察自发电位发生情况。结果　电隔离前心内标测显示 32例患者的 36根大静脉肌袖有自发电活动。以心房 大静脉传入阻滞为终点行大静脉口部消融后 ,16根 (4 4 % )记录到大静脉内自发电活动 ,其中 2根呈偶发的单一电活动 ,11根呈平均频率 (38± 12 )次 /min的缓慢节律 ,3根呈偶发的由 3～ 6个电位组成的短阵快速节律。 15根示大静脉内电活动与心房完全分离 (93 8% ) ,1根左上肺静脉存在大静脉 心房单向传导。结论　射频导管消融电隔离大静脉后 ,出现心房 大静脉传入阻滞时多同时伴有大静脉 心房传出阻断 ,心房 大静脉传入阻滞后大静脉内的电活动频率明显变慢、减少或消失 ,说明窦性心律时的心房 大静脉传导是引起大静脉内电活动不稳定的重要原因 ,射频导管消融技术即使只阻断心房 大静脉单向传导也可通过稳定大静脉内电活动而减少或控制房颤的发作。     

射频导管消融进行心房-肺(或上腔)静脉电隔离治疗阵发性心房颤动的并发症分析

目的总结射频导管消融进行心房 肺静脉和 /或上腔静脉 (合称大静脉 )电隔离治疗阵发性心房颤动 (房颤 )的并发症。方法顽固性阵发性房颤患者 89例 ,在环状标测电极导管指导下行大静脉的射频导管消融电隔离治疗 ,分析出现的各种并发症。结果 89例病人共接受电隔离治疗 10 3次 ,隔离大静脉 2 30根 ,其中肺静脉 2 0 7根 ,上腔静脉 2 3根。出现并发症 10例 ,其中严重迷走神经反射导致的一过性三度房室阻滞引起的晕厥发作 2例 ,脑卒中 2例 ,肺静脉狭窄 4例 (狭窄程度 >5 0 % ) ,术后少量心包积血 2例 ,并发症的总发生率为 11%。结论射频导管消融进行心房 肺和 /或上腔静脉电隔离治疗阵发性房颤可出现各种并发症 ,多数并发症可通过采取相应的措施使之减少或避免 ,其中肺静脉狭窄和脑卒中为最棘手的并发症 ,应予以高度重视。     

冷冻直导管行肺静脉节段消融治疗心房颤动的短期效果

目的 探讨使用冷冻直导管节段消融肺静脉治疗心房颤动(房颤)的可行性和短期治疗效果.方法 选择临床确诊阵发性房颤患者11例,采用6 mn冷冻直导管、Lasso导管标测肺静脉电位,节段消融电隔离肺静脉,肺静脉电位消失30 min为消融隔离成功.结果 平均消融术时间(252.55±51.99)min,曝光时间(35.65±9.88)min.共隔离36根肺静脉,平均每根静脉冷冻(7.9±4.1)次.消融即刻成功率100%.平均随访(8.73±4.15)个月,短期成功率81.8%.结论 冷冻直导管节段消融肺静脉治疗房颤的短期效果较好.     

阵发性心房颤动心房-大静脉电隔离后复发病例分析及再消融

目的 对心房-肺静脉(或上腔静脉)射频消融电隔离(电隔离)术后随访2～12(6.53±4.10)个月内的心房颤动(房颤)复发病例进行再次心内电生理检查及射频消融治疗,探讨电隔离治疗后房颤复发的可能原因,评估再次电隔离的效果。方法 共9例病人,男性8例,女性1例,年龄(53.3±13.2)岁。对上次已作电隔离和上次未进行电隔离的肺静脉和上腔静脉逐一进行标测,对存在心房-静脉传导的静脉进行射频消融心房-静脉电隔离。结果 9例患者上次射频消融电隔离总共22根静脉(19根肺静脉和3根上腔静脉)中,经电生理标测发现其中17根静脉(15根肺静脉和2根上腔静脉)恢复了静脉-心房传导。对这些静脉以及上次未进行电隔离的8根静脉进行射频消融电隔离。术后随访1～15(7.22±5.04)个月,7例病人无房颤复发,2例病人发作次数明显减少。结论 静脉-心房传导恢复及遗留未进行电隔离的大静脉可能是房颤复发的原因,对复发病例,再次射频消融治疗是安全和有效的。     

Lasso环形标测电极导管指导阵发性心房颤动肺静脉电隔离

探讨在Lasso环形标测电极导管指导下对阵发性心房颤动 (PAF)患者行肺静脉电隔离术的安全性、有效性。顽固性PAF患者 30例 ,男 19例 ,年龄 5 3± 15 (41～ 70 )岁 ,在肺静脉口用Lasso环形电极导管对肺静脉逐一进行标测 ,于肺静脉最早的心房 肺静脉电位处消融 ,电学隔离肺静脉。消融温度控制在 5 0℃ ,功率 2 5～ 35W。结果 :电学隔离肺静脉 6 9根 ,其中左上肺静脉 2 8根、左下肺静脉 2 0根、右上肺静脉 15根、右下肺静脉 6根 ,电隔离成功6 5根 ;电隔离上腔静脉 6根 ,左房后游离壁异位兴奋灶消融 8个 ,无手术相关并发症。即刻成功率 94 %。随访10 .1± 5 .1(5～ 2 2 )个月 ,成功率 (无心房颤动发作 ) 6 1%。结论 :在Lasso环形标测电极导管指导下对PAF患者行肺静脉电隔离术安全有效 ,是一种很有前途的治疗PAF的消融方法。     

盐水灌注导管电隔离心房-肺(或上腔)静脉治疗阵发性心房颤动的评价

目的评价盐水灌注导管电隔离心房-肺(或上腔)静脉的效果及安全性。方法69例阵发性心房颤动(房颤)患者,男48例,女21例,平均年龄(55±10)岁,平均病史(4.2±1.1)年。所有患者均采用盐水灌注电极进行肺静脉口部节段性消融,电隔离终点为环状标测电极标测的肺静脉电位全部消失。术后随访症状,心电图及24h动态心电图,以无临床症状及无房颤的心电图证据判定为成功。结果69例共电隔离肺静脉206根,上腔静脉11根,右上肺静脉口外点消融1例。即刻电隔离成功率100%,放电时间(2902.0±1326.3)s。随访时间(118.1±69.7)天,成功率71%。结论应用盐水灌注导管电隔离心房-肺(或上腔)静脉消融安全有效,未见严重并发症发生。     

射频导管消融肺静脉电隔离过程中残存静脉电位的鉴别诊断

心房颤动(房颤)的非药物治疗是近年来的研究热点，国内外许多临床研究证明应用射频导管消融技术成功电隔离肺静脉可以有效预防房颤的复发。环状标测导管指导下的节段性消融肺静脉电隔离成功的指标为，窦性心律或心房内不同部位起搏时肺静脉电位消失、静脉与心房之间的电活动分离。在肺静脉电隔离过程中常碰到较明显的静脉电位被成功消融后，     

Lasso环状标测电极导管指导心房颤动持续过程中心脏大静脉电隔离

目的:报道2例心房颤动(房颤)持续过程中Lasso环状标测电极导管(Lasso电极)指导心脏大静脉 (大静脉)电隔离治疗。方法:2例患者临床症状和心电图记录提示分别为阵发性房颤(PAF)和持续性房颤。经股静脉和颈内静脉穿刺置入右心室和冠状静脉窦电极导管,并行房间隔穿刺和选择性大静脉造影。置入10极 Lasso电极进行大静脉标测。应用普通温控消融导管以局部异常电活动相对最早或频率最快、最紊乱处开始消融,在房颤持续过程中电隔离大静脉至左房连接处,以房颤终止和异常电活动消失或后者与心房电活动无关为消融终点。结果:2例患者共消融7条大静脉。1例PAF患者完成上腔静脉(SVC)和右上肺静脉(RSPV)电隔离后,消融左上肺静脉(LSPV)过程中房颤终止。另1例持续性房颤患者完成SVC、RSFV、LSPV及右下肺静脉电隔离,加做左房峡部、三尖瓣-下腔静脉峡部线性消融后,同步电复律使房颤转为窦性心律。随访1年,无房颤复发和相关并发症。结论:Lasso电极指导下应用普通温控消融导管可于心房颤动持续过程中电隔离大静脉而治疗房颤。     

导管射频消融电隔离心脏大静脉治疗阵发性心房颤动的并发症分析

目的总结导管射频消融电隔离肺静脉和(或)上腔静脉(大静脉)治疗阵发性房颤的并发症与合并症. 方法顽固性阵发性房颤患者89例,在环状标测电极指导下行大静脉的导管射频消融电隔离治疗,如能确定触发房颤的靶大静脉,则行靶大静脉的电隔离,如不能确定靶肺静脉,则经验性地行主要肺静脉(双上肺静脉和左下肺静脉)的电隔离,术后重复肺静脉造影.     

Pathogenesis of carcinoma of the papilla of Vater

Most adenomas and carcinomas of the small intestine and extrahepatic bile ducts arise in the region of the papilla of Vater. In familial adenomatous polyposis (FAP) it is the main location for carcinomas after proctocolectomy. In many cases symptoms due to stenosis lead to diagnosis at an early tumor stage. In about 80%, curative intended resection is possible. Operability is the most relevant prognostic factor. Most ampullary carcinomas resp. carcinomas of the papilla of Vater develop from adenomatous or flat dysplastic precursor lesions. They can be sited in the ampulloduodenal part of the papilla of Vater, which is lined by intestinal mucosa. They also can develop in deeper parts of the ampulla, which are lined by pancreaticobiliary duct mucosa. Intestinal-type adenocarcinoma and pancreaticobiliary-type adenocarcinoma represent the main histological types of ampullary carcinoma. Furthermore, there exist unusual types and undifferentiated carcinomas. Many carcinomas of intestinal type express the immunohistochemical marker profile of intestinal mucosa (keratin 7?, keratin 20+, MUC2+). Carcinomas of pancreaticobiliary type usually show the immunohistochemical profile of pancreaticobiliary duct mucosa (keratin 7+, keratin 20?, MUC2?). Even poorly differentiated carcinomas, as well as unusual histological types, may conserve the marker profile of the mucosa they developed from. These findings underline the concept of histogenetically different carcinomas of the papilla of Vater which develop either from intestinal- or from pancreaticobiliary-type mucosa of the papilla of Vater. Molecular alterations in ampullary carcinomas are similar to those of colorectal as well as pancreatic carcinomas, although they appear at different frequencies. In future studies, molecular alterations in ampullary carcinomas should be correlated closely with the different histologic tumor types. Consequently, the histologic classification should reflect the histogenesis of ampullary tumors from the two different types of papillary mucosa.     

Demonstration of the mechanism of action of biguanides

Summary Palmitic acid oxidation in rat diaphragm homogenate is depressed by biguanide concentrations that are still incapable of inhibiting oxidative phosphorylation. Glucose oxidation is not directly effected by the same biguanide concentrations: however, the inhibitory effect of palmitic acid on glucose oxidation is partly removed by biguanides. Inhibition of fatty acid oxidation, which accounts for most of the metabolic effects caused by these drugs, can be regarded as the fundamental mechanism of action of biguanides. There is some evidence suggesting that these drugs might interact with carnitine, thus preventing long-chain fatty acids from being transported across the mitochondrial membrane to the site of oxidation. Traduzione a cura degli AA.     

胰岛素瘤的解剖分布特点分析

目的胰岛素瘤是最常见的胰腺神经内分泌肿瘤，因其临床表现多样，导致诊断困难。影像学诊断尤其是超声内镜(EUS)在胰岛素瘤的诊断中起着重要作用，拥有较高的敏感性和特异性。本研究拟通过明确胰岛素瘤的解剖分布特点，以期有助于提高影像学的诊断准确率和降低漏诊率，尤其是在教育和培训实践中对于EUS的学习者更具有指导价值。 方法回顾性分析解放军总医院第一医学中心病案资料数据库1993年1月至2019年11月经外科手术、病理确诊为胰岛素瘤的患者的临床资料，检索方法采取搜索术后病理诊断为"胰岛素瘤"的病例，通过查阅病例的方法，提取出胰岛素瘤的大小和解剖分布等数据，进一步分析其特点。 结果共检索到确诊为胰岛素瘤的患者116例，其中，男45例、女71例，年龄13～76岁，平均年龄(44.4±14.85)岁。胰岛素瘤单发110例(94.8%)、多发6例(5.2%)。位置分布：头颈部46例(39.7%)，单发45例、多发1例；体尾部68例(58.6%)，单发65例、多发3例；全胰腺多发2例(1.7%)。病变大小特点：最大径0.4～3.4 cm，平均大小(1.53±0.58)cm。≤1 cm 29例、>1 cm而≤1.5 cm41例、>1.5 cm而≤2.0 cm28例，≤3 cm 15例，>3 cm 3例。年龄与肿瘤的大小相关，≤44岁患者肿瘤平均大小为(1.36±0.51)cm、>44岁患者肿瘤平均大小为(1.70±0.60)cm，P<0.05。头颈部的肿瘤大于体尾部的肿瘤，头颈部肿瘤平均大小(1.66±0.63)cm，体尾部(1.42±0.52)cm，P<0.05。 结论胰岛素瘤在胰腺体尾部较头颈部更好发；绝大多数单发，但可以全胰腺多发；多数小于1.5 cm，肿瘤的大小与患者年龄和肿瘤的解剖分布相关。     

氯硝柳胺悬浮剂的毒性评价

目的评价氯硝柳胺悬浮剂的毒性，为现场大规模应用灭螺提供依据。方法按照中华人民共和国国家标准GB 15670-1995《农药登记毒理学试验方法》和鱼类毒性试验方法进行。结果经口、经皮肤的LDso雌、雄性大鼠均>5 000 mg/kg，经呼吸道的LCso雌、雄性大鼠均>5 000mg/m3，该药经口、经皮肤、经呼吸道毒性均属微毒类药物；兔眼用药后，观察期内无不良反应，对眼无刺激性；皮肤用药后对皮肤无刺激性。与氯硝柳胺原药、氯硝柳胺乙醇胺盐原药和氯硝柳胺乙醇胺盐可湿性粉剂相比，氯硝柳胺悬浮剂对鱼急性毒性最低。结论氯硝柳胺悬浮剂属微毒类药物，对鱼的毒性低于其乙醇胺盐可湿性粉剂，适合于现场应用。     

Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease

BACKGROUND AND AIM: Both the clinical presentation and the degree of mucosal damage in coeliac disease vary greatly. In view of conflicting information as to whether the mode of presentation correlates with the degree of villous atrophy, we reviewed a large cohort of patients with coeliac disease. PATIENTS AND METHODS: We correlated mode of presentation (classical, diarrhoea predominant or atypical/silent) with histology of duodenal biopsies and examined their trends over time. RESULTS: The cohort consisted of 499 adults, mean age 44.1 years, 68% females. The majority had silent coeliac disease (56%) and total villous atrophy (65%). There was no correlation of mode of presentation with the degree of villous atrophy (p=0.25). Sixty-eight percent of females and 58% of males had a severe villous atrophy (p=0.052). There was a significant trend over time for a greater proportion of patients presenting as atypical/silent coeliac disease and having partial villous atrophy, though the majority still had total villous atrophy. CONCLUSIONS: Among our patients the degree of villous atrophy in duodenal biopsies did not correlate with the mode of presentation, indicating that factors other than the degree of villous atrophy must account for diarrhoea in coeliac disease.     

CagA-Hp抗体IgG与胃炎的组织学分析

研究幽门螺杆菌(Hp)感染与胃炎的关系。方法对204例慢性胃炎患者胃粘膜进行观察分析,并测定其中137例Hp阳性患者血清CagA-Hp抗体IgG水平,与组织学对照。结果慢性萎缩性胃炎伴肠上皮化生患者血清CagA抗体IgG明显高于对照组(P＜0.01);其他类型胃炎患者血清CagA抗体IgG水平无明显增高(P＞0.05)。结论CagA-Hp可能是导致慢性萎缩性胃炎伴肠上皮化生的因素之一,对这类患者应密切随访观察。     

慢阻肺急性加重期患者预后的影响因素分析

目的探讨慢性阻塞性肺病急性加重期(AECOPD)患者预后的相关危险因素。方法回顾性调查、收集58例AECOPD患者可能影响其预后的相关因素,并对其分别进行单因素分析。并进行Logistic多元逐步回归进行多因素分析,筛选影响AECOPD患者预后的独立危险因素。结果单因素分析后将结果 P0.1的因素纳入多因素Logistic回归,分析发现是否合并呼吸衰竭、气促程度、白细胞计数、APACHEⅡ、应用抗氧化剂、慢阻肺治疗依从性为影响AECOPD患者预后不佳的独立因素(P0.05)。结论根据AECOPD患者预后的独立危险因素,及早判断,选择合适的后续治疗方案,对提高其生存率及生存质量具有重要意义。     

血吸虫童虫生长发育及其机制的研究进展

血吸虫童虫是宿主免疫系统攻击的重要靶标,包括皮肤型、肺型和肝门型童虫。宿主分子对童虫生长发育具有重要作用。童虫生长发育机制包括免疫调节、信号转导、性别发育及凋亡等。肌动蛋白、组织蛋白酶、烯醇化酶和葡萄糖基转移酶等分子为血吸虫童虫生长发育的重要分子。本文对血吸虫童虫生长发育及其机制的研究进展做一综述。     

124例耐多药结核分枝杆菌基因突变特征分析

目的对临床分离的耐多药结核分枝杆菌相关基因的突变特征进行分析。方法对124例耐多药结核分枝杆菌以及50株敏感株的耐药相关基因(包括异烟肼inh A、kat G、oxyR-ahp C间隔区以及利福平rpo B)进行序列测定,分析其基因突变情况。结果异烟肼耐药inh A基因突变率为14.5%;kat G基因突变率为70.2%(87/124),主要位于315位;oxyR-ahp C间隔区突变率为15.3%;inh A、kat G两种基因同时突变率75.0%,三种基因同时突变率为89.5%。利福平rpo B基因突变的检出率高达95.2%,突变主要发生在531、526、516位点。结论我省耐多药菌异烟肼耐药相关基因最常见突变为kat G 315、inh A C-T(-15)、axyR-ahp C间隔区(-10)C-T,利福平为rpo B531、526、516。结合MDR-TB耐药相关基因的特征分析,可以建立一种快速、准确、特异的适合于我省的检测结核菌耐多药性的新方法。     

Results of treatment of fistula-in-ano

To evaluate the application of Parks' classification in the management of patients with fistula-in-ano, a study was undertaken to assess the outcome of surgery, especially with respect to the recurrence rate and alteration of continence. A retrospective analysis of 160 consecutive patients who were classified at the time of operation was conducted. The distribution of fistulas was as follows: intersphincteric, 41.9 percent, transsphincteric, 52.1 percent, suprasphincteric, 1.3 percent, extrasphincteric, 0. A horseshoe extension occurred in 8.8 percent of the fistulas and 3.8 percent did not exactly conform to the classification as they were either complex or combinations of more than one type of fistula. The sole immediate postoperative complication was bleeding, which occurred one week postoperatively and ceased spontaneously (0.7 percent). Alteration in continence occurred in 6 percent of patients with 2.6 percent experiencing temporary incontinence to flatus, 1.3 percent to liquid stool, and 0.7 percent to solid stool. Permanent loss of control for flatus occurred in one patient (0.7 percent) and for liquid stool in one patient (0.7 percent). No patients suffered loss of control for solid stool. Recurrence developed in 6.3 percent of patients, all between five and 25 months postoperatively. Classifcation was found to be a useful guide in the operative management of patients with fistula-in-ano. Read at the joint meeting of the American Society of Colon and Rectal Surgeons with the Section of Colo-Proctology, Royal Society of Medicine, and the Section of Colonic and Rectal Surgery, Royal Australasian College of Surgeons, New Orleans, Louisiana, May 6 to 11, 1984.